KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants

Bibliographic Details
Main Authors:	Heublein, Sabine, Grasse, Katinka, Hessel, Harald, Burges, Alexander, Lenhard, Miriam, Engel, Jutta, Kirchner, Thomas, Jeschke, Udo, Mayr, Doris
Format:	Online
Language:	English
Published:	BioMed Central 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015926/

Similar Items

Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR)
by: Heublein, Sabine, et al.
Published: (2013)

The G-Protein Coupled Estrogen Receptor (GPER/GPR30) is a Gonadotropin Receptor Dependent Positive Prognosticator in Ovarian Carcinoma Patients
by: Heublein, Sabine, et al.
Published: (2013)

Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival
by: Lenhard, Miriam, et al.
Published: (2012)

Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients
by: Scholz, Christoph, et al.
Published: (2012)

The G-Protein-Coupled Estrogen Receptor (GPER/GPR30) in Ovarian Granulosa Cell Tumors
by: Heublein, Sabine, et al.
Published: (2014)

Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer
by: Lenhard, Miriam, et al.
Published: (2013)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
by: GIANNINI, RICCARDO, et al.
Published: (2014)

Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis
by: Sabine Heublein, et al.
Published: (2017-04-01)

Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways
by: Heublein, Sabine, et al.
Published: (2015)

Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients
by: Engelstaedter, Verena, et al.
Published: (2012)

Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer
by: Lenhard, Miriam, et al.
Published: (2012)

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
by: Popovici, Vlad, et al.
Published: (2013)

Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients
by: Heublein, Sabine, et al.
Published: (2015)

Importance of RIP140 and LCoR Sub-Cellular Localization for Their Association With Breast Cancer Aggressiveness and Patient Survival
by: Sophie Sixou, et al.
Published: (2018-10-01)

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
by: Yokota, Tomoya
Published: (2012)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
by: Stefanius, Karoliina, et al.
Published: (2011)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
by: Eklöf, V, et al.
Published: (2013)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
by: Szablewski, Vanessa, et al.
Published: (2013)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
by: BUJKO, MATEUSZ, et al.
Published: (2014)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
by: Daeyoun David Won, et al.
Published: (2017-06-01)

Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations
by: Li, Wenbin, et al.
Published: (2015)

KRAS and BRAF mutational status in colon cancer from Albanian patients
by: Martinetti, Daniela, et al.
Published: (2014)

Analysis of FoxP3+ T-Regulatory Cells and CD8+T-Cells in Ovarian Carcinoma: Location and Tumor Infiltration Patterns Are Key Prognostic Markers
by: Hermans, Cecilia, et al.
Published: (2014)

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
by: Løes, Inger Marie, et al.
Published: (2016)

Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas12
by: Myers, Meagan B., et al.
Published: (2016)

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
by: Richman, Susan D., et al.
Published: (2011)

A New Microarray Substrate for Ultra-Sensitive Genotyping of KRAS and BRAF Gene Variants in Colorectal Cancer
by: Galbiati, Silvia, et al.
Published: (2013)

Multicentric and multifocal versus unifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biology
by: Weissenbacher, Tobias, et al.
Published: (2013)

Heterogeneity of KRAS Mutation Status in Rectal Cancer
by: Jo, Peter, et al.
Published: (2016)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
by: Guedes, Joana G, et al.
Published: (2013)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
by: Modest, D. P., et al.
Published: (2016)

Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
by: Oscar Murcia, et al.

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
by: Markus V. Heppt, et al.
Published: (2017-08-01)

On The Borderline
by: Kayla, Kavanagh
Published: (2010)

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer
by: Mao, Chen, et al.
Published: (2012)

Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing
by: Borràs, Emma, et al.
Published: (2011)

Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations
by: Brandi, Giovanni, et al.
Published: (2012)

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen, Shanxiang, et al.
Published: (2012)

Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature
by: Sahin, Ibrahim Halil, et al.
Published: (2013)

Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
by: Derbel, Olfa, et al.
Published: (2013)